A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder

NCT01970345 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Decision made to terminate due to difficulty in procurement of adequate supply of treatment drug. Decision made on April 2023 to terminate study.

Conditions

Autism Spectrum Disorder

Interventions

DRUG: IGF-1
DRUG: Placebo/saline

Sponsor

Icahn School of Medicine at Mount Sinai

Collaborators

[object Object]